Tecan Group AG · SIX:TECN

Tecan — UBS Global Life Sciences Conference 2011

20 slides from Tecan's conference presentation, Sep 20, 2011

  1. Slide 1: UBS Global Life Sciences Conference

    September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO

  2. Slide 2: Contents

    September 20, 2011 / p2 / UBS GLSC Contents • Introducing Tecan • Strategic Growth Drivers • Financials H1 2011 & Outlook

  3. Slide 3: Introducing Tecan

    September 20, 2011 / p3 / UBS GLSC Introducing Tecan • Provider of instruments and workflow-solutions to the world’s pharma, biotech, diagnostic and forensic laboratories and companies • Our solutions accelerate, automate and enhance the processes in state- of-the-art life sciences laboratories • Gl

  4. Slide 4: Tecan's Products, Business Structure and Markets

    September 20, 2011 / p4 / UBS GLSC Tecan’s Products, Business Structure and Markets Life Sciences Business Partnering Business • Focused on all end-user activities • Focused on all OEM activities • Products marketed under the Tecan • Products sold by partners under brand through own sales & service

  5. Slide 5: Contents

    September 20, 2011 / p5 / UBS GLSC Contents • Introducing Tecan • Strategic Growth Drivers • Financials H1 2011 & Outlook

  6. Slide 6: Strategic Drivers for Sustainable Profitable Growth

    September 20, 2011 / p6 / UBS GLSC Strategic Drivers for Sustainable Profitable Growth Life Sciences Partnering Business Business Sales Channel Expanded Project Leverage Pipeline Increased Innovation to Drive Organic Growth High-Value Services & Consumables Geographic Expansion into Growth Markets I

  7. Slide 7: Strategic Growth Drivers for the Life Sciences Business

    September 20, 2011 / p7 / UBS GLSC Strategic Growth Drivers for the Life Sciences Business Innovation Partnerships for Slide 8 • New family of liquid handling Workflow Solutions platforms and new modules • Various co-operation models in Life Sciences Business • New detection instruments Life Science

  8. Slide 8: Applications & Integrated Workflow Solutions

    September 20, 2011 / p8 / UBS GLSC Applications & Integrated Workflow Solutions Provided by Tecan Provided by Partner Services Software Consumables Life Sciences Business Instruments User Interfaces Reagents Modules 3rd Party Devices Quality & Regulatory

  9. Slide 9: Leveraging Tecan's Sales Channels

    September 20, 2011 / p9 / UBS GLSC Leveraging Tecan’s Sales Channels • Tecan and HP to provide faster, more accurate drug screening • Companies to market new drug-dispensing solution for Life Sciences Business pharmaceutical testing • Tecan will provide exclusive sales, marketing, service and suppor

  10. Slide 10: Strategic Growth Drivers for the OEM Business

    September 20, 2011 / p10 / UBS GLSC Strategic Growth Drivers for the OEM Business OEM Market • Today majority of OEM market is ~$ 8bn* „captive“, i.e. instruments developed by IVD & LSR companies ~$ 6bn* „captive“ • Trend towards outsourcing Partnering Business • Focus on faster time to market, cost

  11. Slide 11: Tecan's Broad OEM Offering

    September 20, 2011 / p11 / UBS GLSC Tecan’s Broad OEM Offering Integrated Solutions • Concepts developed by Tecan and showcased to potential partners • Integrating instrument, plastic consumables and enabling reagents Dedicated Solutions Plastic Consumables Customer Service & Partnering Business P14

  12. Slide 12: P14 & P16: Two Major OEM Agreements

    September 20, 2011 / p12 / UBS GLSC P14 & P16: Two Major OEM Agreements P14 (announced 11/2010) • Building on established partnership with global diagnostics company • Tecan to develop and supply a next generation dedicated diagnostics instrument and a corresponding plastic consumable Partnering Bus

  13. Slide 13: Signed OEM Development & Supply Contracts

    September 20, 2011 / p13 / UBS GLSC Signed OEM Development & Supply Contracts 2010 2011 2012 2013 Liquid Handling Solutions Supply of 9 instruments Under development / recently launched: DNA Extractor (MDx) High Throughput HTA Mid Throughput MTA Partnering Business (PoC MDx) Enigma ML (MDx) Configur

  14. Slide 14: Our OEM Instrument Partners

    September 20, 2011 / p14 / UBS GLSC Our OEM Instrument Partners Liquid Handling Solutions Partnering Business Detection Instruments

  15. Slide 15: Strategic Growth Driver: Services & Consumables

    September 20, 2011 / p15 / UBS GLSC Strategic Growth Driver: Services & Consumables Services & Consumables sales S&C as a % of total sales Life Sciences Business Services Consumables Services & Consumables Instruments 120 100 80 31.2% 30.6% 40% 60 40 CHF (mio) 20 2009 2010 Goal 2014 0 2008 2009 2010

  16. Slide 16: Contents

    September 20, 2011 / p16 / UBS GLSC Contents • Introducing Tecan • Strategic Growth Drivers • Financials H1 2011 & Outlook

  17. Slide 17: H1 2011: Strong Business Performance

    September 20, 2011 / p17 / UBS GLSC H1 2011: Strong Business Performance Sales 200 • Substantial sales growth 180 • +12.3% in local currencies; +2.2% in CHF 160 140 Rest of World • Life Sciences Business (end customers) 120 Asia +18.1% in local currencies 100 Europe 80 • Partnering Business (OEM cus

  18. Slide 18: Outlook for Full Year 2011

    September 20, 2011 / p18 / UBS GLSC Outlook for Full Year 2011 Sales FY 2011 Profitability FY 2011 As of March 10, 2011 EBIT Margin of 12-13% Mid-single-digit sales growth in Based on average FX rates of: local currencies 1.30 EUR/CHF and 1.00 USD/CHF Updated guidance as of August 18, 2011 Sales for

  19. Slide 19: Next Events and Contact

    September 20, 2011 / p19 / UBS GLSC Next Events 2011: December 1: Analyst & Investor Day 2012: March 8: Full Year 2011 financial results April 18: Annual Shareholder Meeting Contact Martin Braendle Head of Corporate Communications & Investor Relations Phone: +41 (0) 44 922 84 30 investor@tecan.com w

  20. Slide 20: Safe Harbor Statement

    Safe Harbor Statement All statements in this presentation not referring to historical facts are predictions of the future and constitute no guarantee whatsoever of future performances. They are subject to risks and uncertainties including, but not limited to, future global economic conditions, excha

Tecan Group — UBS Global Life Sciences Conference 2011 on 6ix